Chengdu Wesker Biomedical

Chengdu Wesker Biomedical is a Chinese biotechnology company specializing in the development and manufacturing of innovative vaccines and immunotherapy products. Founded by scientists from the West China Medical Center of Sichuan University, the company utilizes a high-throughput insect cell expression platform and an mRNA technology platform. Its lead product, Coviccine, was one of the first recombinant protein COVID-19 vaccines to receive emergency use authorization in China. Beyond infectious diseases, Wesker is expanding its pipeline into therapeutic cancer vaccines and cell therapies. The company maintains large-scale GMP manufacturing facilities in Chengdu to support its rapid development and commercialization efforts. Wesker is backed by a diverse group of investors, including major state-owned funds and international venture capital firms.